Relmada Therapeutics, Inc. (RLMD) Stock

Relmada Therapeutics, Inc. (RLMD) is a Healthcare stock trading at $6.70 (as of 2026-06-18), with a market capitalization of $756.26M and a trailing P/E of -6.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing products for central nervous system diseases and other disorders. Its lead candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), an N-methyl-D-aspartate receptor antagonist in Phase 3 trials for major depressive disorder treatment in adults.

Valuation — source: SEC EDGAR (first-party)
Price	$6.70
Market Cap	$756.26M
P/E Ratio	-6.6
Price / Book	3.46
DCF Value (model)	$-7.40
DCF Upside vs Price	-210.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$1.40M
Net Margin	-4110.7%
Return on Equity	-26.9%
Current Ratio	18.26
Revenue Growth (YoY)	-60.5%
EPS Growth (YoY)	-45.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	44.94 (safe)

Valuation vs Sector & Industry
Stock P/E	-6.6
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-131.7%
vs Industry	-138.9%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	JANUS HENDERSON GROUP PLC ($76.89M)
Institutional Holders Tracked	10
Congressional Trades (recent)	2

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Sergio Traversa
Employees	17
Country	US
IPO Date	2014-06-20

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.